Subscribe to RSS
DOI: 10.1055/a-2549-5784
Time Adjustment of Hydrocortisone Doses During Shift Work in Patients with Adrenal Insufficiency
Supported by: Charité Clinician Scientist Program to Tina Kienitz
Abstract
Shift work causes a disruption between the circadian system and the external light-dark cycle, but also a misalignment between various levels of the circadian system. There is no information on patients with adrenal insufficiency (AI) who are working shifts. The objective of the study was to analyze the hormone replacement therapy with hydrocortisone (HC) and the adaptation scheme in patients with AI on shifts. Patients working on shifts (n=15) from two German endocrine centers received a questionnaire regarding their therapy scheme, dose adaptations, working shifts, dose adaptations during working shifts, and occurrence of adrenal crisis. We observed that 20% of patients stated that they experience difficulties taking glucocorticoid replacement on time, 40% of patients reported these difficulties to occur only occasionally. Consequently, nearly half of the patients had forgotten to take their replacement therapy at some point. More than 50% of patients reported an adrenal crisis during the last two years. The timely adaptation of HC or of modified-release HC during shifts was very inhomogeneous. In conclusion, the adaptation schemes for HC dosing during shift work are currently not evidence-based but opinion-driven. Our findings highlight the need for further investigations of shift workers with AI.
Keywords
hydrocortisone - Addison’s disease - circadian rhythm - secondary adrenal insufficiency - modified-release hydrocortisonePublication History
Received: 28 December 2024
Accepted after revision: 02 March 2025
Accepted Manuscript online:
02 March 2025
Article published online:
10 April 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Allolio B. Adrenal crisis. Eur J Endocrinol 2015; 172: R115-R124
- 2 Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23: 167-179
- 3 Hahner S, Ross RJ, Arlt W. et al. Adrenal insufficiency. Nat Rev Dis Primers 2021; 7: 19
- 4 Bancos I, Hahner S, Tomlinson J. et al. Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 2015; 3: 216-226
- 5 Bornstein SR, Allolio B, Arlt W. et al. Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 364-389
- 6 Quinkler M, Beuschlein F, Hahner S. et al. Nebennierenrinden-insuffizienz – Lebensbedrohliche erkrankung mit vielfältigen ursachen. Dtsch Arzteblatt Int 2013; 110: 882-888
- 7 Husebye ES, Allolio B, Arlt W. et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med 2014; 275: 104-115
- 8 Oksnes M, Ross R, Løvås K. Optimal glucocorticoid replacement in adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2015; 29: 3-15
- 9 Paragliola RM, Corsello SM. Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. Minerva Endocrinol 2018; 43: 183-197
- 10 Murray RD, Ekman B, Uddin S. et al. Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity – data from the EU-AIR. Clin Endocrinol (Oxf) 2017; 86: 340-346
- 11 Quinkler M, Nilsen RM, Zopf K. et al. Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 2015; 172: 619-626
- 12 Johannsson G, Bergthorsdottir R, Nilsson AG. et al. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009; 161: 119-130
- 13 Nilsson AG, Bergthorsdottir R, Burman P. et al. Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur J Endocrinol 2017; 176: 715-725
- 14 Guarnotta V, Stefano CDi, Tomasello L. et al. Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study. Eur J Endocrinol 2024; 191: 300-311
- 15 Giordano R, Guaraldi F, Berardelli R. et al. Dual-release hydrocortisone in Addison’s disease – a review of the literature. Eur Endocrinol 2014; 10: 75-78
- 16 Dineen R, Martin-Grace J, Ahmed KMS. et al. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study. Eur J Endocrinol 2021; 184: 253-265
- 17 Dineen RA, Martin-Grace J, Ahmed KMS. et al. Tissue glucocorticoid metabolism in adrenal insufficiency: a prospective study of dual-release hydrocortisone therapy. J Clin Endocrinol Metab 2023; 108: 3178-3189
- 18 Tucci L, Fanelli F, Improta I. et al. Monitoring adrenal insufficiency through salivary steroids: a pilot study. Eur J Endocrinol 2024; 190: 327-337
- 19 Veldhuis JD, Iranmanesh A, Lizarralde G. et al Downloaded from [Internet]. Am J Physiol Endocrinol Metab at Charité-Med. Bibliothek 1989; 257 Available from http://ajpendo.physiology.org/
- 20 Grossman A, Johannsson G, Quinkler M. et al. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 2013; 169: R165-R175
- 21 Erichsen MM, Løvås K, Fougner KJ. et al. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. Eur J Endocrinol 2009; 160: 233-237
- 22 Sherlock M, Ayuk J, Tomlinson JW. et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31: 301-342
- 23 Skov J, Sundstrom A, Ludvigsson JF. et al. Sex-specific risk of cardiovascular disease in autoimmune Addison disease-a population-based cohort study. J Clin Endocrinol Metab 2019; 104: 2031-2040
- 24 Schulz J, Frey KR, Cooper MS. et al. Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur J Endocrinol 2016; 174: 531-538
- 25 Løvås K, Gjesdal CG, Christensen M. et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol 2009; 160: 993-1002
- 26 Hahner S, Spinnler C, Fassnacht M. et al. High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 2015; 100: 407-416
- 27 Boivin DB, Boudreau P, Kosmadopoulos A. Disturbance of the circadian system in shift work and its health impact. J Biol Rhythms 2022; 37: 3-28
- 28 Fritschi L, Glass DC, Heyworth JS. et al. Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses 2011; 77: 430-436
- 29 Szosland D. Shift work and metabolic syndrome, diabetes mellitus and ischaemic heart disease. Int J Occup Med Environ Health 2010; 23: 287-291
- 30 Hemmer A, Mareschal J, Dibner C. et al. The effects of shift work on cardio-metabolic diseases and eating patterns. Nutrients 2021; 13: 4178
- 31 Morris CJ, Aeschbach D, Scheer FAJL. Circadian system, sleep and endocrinology. Mol Cell Endocrinol 2012; 349: 91-104
- 32 Scheer FAJL, Hilton MF, Mantzoros CS. et al. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A 2009; 106: 4453-4458
- 33 Oster H, Challet E, Ott V. et al. The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocr Rev 2017; 38: 3-45
- 34 Hennig J, Kieferdorf P, Moritz C. et al. Changes in cortisol secretion during shiftwork: implications for tolerance to shiftwork?. Ergonomics 1998; 41: 610-621
- 35 Touitou Y, Motohashi Y, Reinberg A. et al. Effect of shift work on the night-time secretory patterns of melatonin, prolactin, cortisol and testosterone. Eur J Appl Physiol Occup Physiol 1990; 60: 288-292
- 36 Weibel L, Spiegel K, Follenius M. et al. Internal dissociation of the circadian markers of the cortisol rhythm in night workers. Am J Physiol 1996; 270: E608-E613
- 37 Roden M, Koller M, Pirich K. et al. The circadian melatonin and cortisol secretion pattern in permanent night shift workers. Am J Physiol 1993; 265: R261-R267
- 38 Burger-Stritt S, Eff A, Quinkler M. et al. Standardised patient education in adrenal insufficiency: a prospective multi-centre evaluation. Eur J Endocrinol 2020; 183: 119-127
- 39 Mullins HM, Cortina JM, Drake CL. et al. Sleepiness at work: a review and framework of how the physiology of sleepiness impacts the workplace. J Appl Psychol 2014; 99: 1096-1112
- 40 Chapman SCE, Llahana S, Carroll P. et al. Glucocorticoid therapy for adrenal insufficiency: nonadherence, concerns and dissatisfaction with information. Clin Endocrinol (Oxf) 2016; 84: 664-671
- 41 Bostock F, Mortimore G. Considering the impact of shift working on health. Br J Nurs 2024; 33: 120-124
- 42 Akerstedt T. Shift work and disturbed sleep/wakefulness. Sleep Med Rev 1998; 2: 117-128
- 43 Ohayon MM, Lemoine P, Arnaud-Briant V. et al. Prevalence and consequences of sleep disorders in a shift worker population. J Psychosom Res 2002; 53: 577-583
- 44 Plat L, Leproult R, L’hermite-Baleriaux M. et al. Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. J Clin Endocrinol Metab 1999; 84: 3082-3092
- 45 Darji M, Pannain S, Sam S. et al. THU611 circadian misalignment of melatonin secretion in adrenal insufficiency (AI). J Endocr Soc 2023; 7: bvad114.141